ArticleRSC advances2025
Elimination mechanism of vanillin from non-phenolic β-O-4-type terminals formed in guaiacyl lignin: a combined kinetic and theoretical study.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alkaline aerobic oxidation of lignin to vanillin (4-hydroxy-3-methoxybenzaldehyde) has been employed as an industrial method for producing bio-based low-molecular-weight aromatic compounds. To deepen the molecular-level understanding of this reaction, we have been investigating the vanillin formation mechanism from native softwood lignin. One of the major reaction pathways involves oxidative degradation of β-O-4-type internal units, followed by alkaline-induced elimination of vanillin from the resulting vanillin end group. This study examined the reaction mechanism of a model compound, 4-[2-(3-ethoxy-4-methoxyphenyl)-2-hydroxy-1-(hydroxymethyl)ethoxy]-3-methoxybenzaldehyde, VE
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.